Drug intelligence / Profile preview

PTGER3 siRNA-2'-F-PS2-DOPC

Development stage: Preclinical
Lead developer: University of Texas MD Anderson Cancer Center
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Intravenous, Intraperitoneal

Overview

PTGER3 siRNA-2'-F-PS2-DOPC is an investigational RNA interference (RNAi) therapeutic designed to target the Prostaglandin E2 Receptor EP3 (PTGER3). Developed primarily as a research tool at MD Anderson Cancer Center, this compound consists of a small interfering RNA (siRNA) incorporating 2'-fluoro (2'-F) and phosphorodithioate (PS2) chemical modifications to enhance stability and potency. The modified siRNA is encapsulated in 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) neutral liposomes for systemic delivery. PTGER3 is implicated in tumor-associated angiogenesis, tumor growth, and chemoresistance in various cancers. Preclinical studies in mouse xenograft models of cisplatin-resistant ovarian cancer have demonstrated that this therapeutic can reduce tumor cell proliferation, inhibit angiogenesis, and restore sensitivity to cisplatin.

Other names: DOPC-2'-F-PS2-PTGER3 siRNA

Targets

PTGER3 (Prostaglandin E2 receptor EP3 subtype)

Beyond the preview

Go deeper on PTGER3 siRNA-2'-F-PS2-DOPC.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PTGER3 siRNA-2'-F-PS2-DOPC.

Explore the full profile